Gly MCA New
Chemical Name: N-[(3α,5β,6β,7β)-3,6,7-Trihydroxy-24-oxocholan-24-yl]glycine
Biological ActivityFarnesoid X receptor (FXR) antagonist. Accumulates in ileum and inhibits FXR signaling exclusively in intestine. Inhibits or reverses high-fat diet-induced and genetic obesity, insulin resistance and hepatic steatosis in mice. Reduces obesity and metabolic syndrome in obese mice. Orally bioavailable.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction.
Jiang et al.
Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism.
Wahlström et al.
Cell Metab., 2016;24:41
Gut-brain cross-talk in metabolic control.
Clemmensen et al.
No product specific FAQs exist for this product, however you mayView all Small Molecule FAQs
Reviews for Gly MCA
There are currently no reviews for this product. Be the first to review Gly MCA and earn rewards!
Have you used Gly MCA?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image